The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Monoclonal antibody-based immunotherapy is now considered to be a main component of
cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies …

Tebotelimab, a bispecific PD-1× LAG-3 DART molecule that blocks both PD-1 and LAG-3,
was investigated for clinical safety and activity in a phase 1 dose-escalation and cohort …

Cancer immunotherapy has been accompanied by promising results over the past few
years. Programmed Cell Death Protein 1 (PD-1) plays a vital role in inhibiting immune …

Immunotherapy holds the potential to induce durable responses, but only a minority of
patients currently respond. The etiologies of primary and secondary resistance to …

HER2 is an established therapeutic target in a large subset of women with breast cancer; a
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …

Abstract Background The 16th St. Gallen International Breast Cancer Conference 2019 in
Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies …

Background HER2-positive metastatic breast cancer is incurable and new treatments are
needed. Addition of atezolizumab to trastuzumab emtansine might potentiate anticancer …

Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–
25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the …